SCHEMBL2459317

SCHEMBL2459317

CC(C)COC(=O)N1CCN(c2ccc(C(=O)Nc3ccc(O)cc3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.57
▸ KDM4E B2RXH2 5/20 0.57
▸ GAA P10253 3/20 0.57
▸ LMNA P02545 2/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ ALDH1A1 P00352 5/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ USP2 O75604 4/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ TP53 P04637 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ POLB P06746 2/20 0.52
▸ HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11889801 0.89 MAPT (0.74) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL5274074 0.87 MAPT (0.74) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL11889802 0.85 MAPT (0.57) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL11889746 0.83 MAPT (0.55) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL11889651 0.83 MAPT (0.65) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL12306055 0.81 RAB9A (0.63) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL11889725 0.81 MAPT (0.56) MAPTKDM4EGAALMNASMN1; SMN2
SCHEMBL2454198 0.81 MAPT (0.64) MAPTKDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL2455257 0.81 MAPT (0.64) MAPTKDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL11889739 0.81 CA12 (0.60) MAPTKDM4EGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799663-B1 Modulators of HCV replication ANGELETTI P IST RICHERCHE BIO (IT) 2012-08-01 — — EP disclosed
US-8012982-B2 Modulators of HCV replication ISTITUTO DI RICERCHE BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-09-06 — — US disclosed
US-20090069344-A1 Modulators of hcv replication ISTITUTO DI RICERCHE BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-03-12 — — US disclosed
EP-1799663-A1 MODULATORS OF HCV REPLICATION Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-06-27 — — EP disclosed
WO-2006038039-A1 MODULATORS OF HCV REPLICATION ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069344-A1 Modulators of hcv replication EIF2AK2, IRF3, IFNAR1 MAPT 4662/4885KDM4E 2063/4885GAA 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback